Synthetic Lethality Explained: Targeting Cancer’s DNA Repair Weaknesses

Can precision oncology help identify cancer’s genetic weaknesses and turn them into therapeutic opportunities? In this episode of "Rx for Biotech", host Chris Leidli speaks with Oren Gilad, CEO of Aprea Therapeutics, about the rapidly evolving field of synthetic lethality, DNA damage response, and targeted cancer therapies designed to exploit vulnerabilities in cancer cells. Oren shares how his scientific journey began at the University of Pennsylvania, where early experiments studying ATR helped shape the foundation for Aprea’s current cancer drug development strategy. That work led to a central insight behind synthetic lethality: cancer cells with specific genetic mutations may become highly dependent on certain DNA repair and checkpoint pathways for survival. Aprea is developing a pipeline of precision oncology therapies focused on what Oren describes as multiple targets in one critical pathway, including WEE1, ATR, p53 reactivation, and DYRK1 inhibition. A major focus of the conversation is APR-1051, Aprea’s investigational oral WEE1 inhibitor, which is being studied in patients with cancers carrying specific genetic alterations. Oren explains how WEE1 functions as a checkpoint in cell division, why cancer cells can become especially dependent on this pathway, and how inhibiting WEE1 may selectively target tumor cells while aiming to preserve a wider therapeutic window. Chapters: 00:00 Synthetic Lethality: A Precision Cancer Strategy 00:58 Meet Oren Gilad, CEO of Aprea Therapeutics 01:27 From Cancer Biology Research to Aprea Therapeutics 02:16 The Bench Experiment That Shaped Aprea’s Mission 03:21 Targeting Genetic Mutations with Precision Medicine 04:08 From Scientist to Biotech CEO 05:08 Why Synthetic Lethality Is Clinically and Commercially Validated 06:34 APR-1051: Aprea’s WEE1 Inhibitor 08:10 DNA Damage Response and Cancer Cell Vulnerabilities 09:26 What Is Synthetic Lethality? 11:00 ASCO Data: Tumor Shrinkage and Early Clinical Signals 12:14 How APR-1051 Is Administered 13:13 Designing for a Wider Therapeutic Window 15:06 Biomarkers, Patient Selection, and Cancer Mutations 17:04 What Success Could Mean for Patients 18:08 ATRN-119: Aprea’s ATR Inhibitor Program 19:28 Why Safety Matters for Combination Therapy 20:05 The Rationale for Oncology Combination Strategies 21:26 Financing, Partnering, and Pharma Interest 22:11 Upcoming Clinical and Corporate Milestones 23:23 Next Clinical Readouts and Future Data Updates 24:18 Closing Thoughts 24:50 Rx for Biotech Listener Resources Oren also shares a personal reflection on why reducing cancer treatment toxicity matters, emphasizing the goal of shrinking tumors while minimizing the burden of therapy for patients. This episode is especially relevant for anyone interested in precision medicine, targeted cancer therapy, DNA repair, synthetic lethality, oncology clinical trials, cancer biomarkers, and the future of drug development. Subscribe to "Rx for Biotech" channel for conversations with biotech CEOs, scientists, physicians, and industry leaders developing the next generation of personalized medicines. This podcast is for educational purposes only and should not be interpreted as medical advice. Investigational therapies discussed in this episode have not necessarily been established as safe or effective by regulatory authorities. #SyntheticLethality #PrecisionOncology #CancerResearch #DNARepair #TargetedTherapy #CancerTreatment #Oncology #Biotechnology #Biotech #ClinicalTrials #RxForBiotech